Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study

MLA

Isfordink, Cas J., et al. Reasons for Not Commencing Direct-Acting Antiviral Treatment despite Unrestricted Access for Individuals with HIV and Hepatitis C Virus: A Multinational, Prospective Cohort Study. Jan. 2023. EBSCOhost, https://doi.org/10.48350/180676.

APA

Isfordink, C. J., Boyd, A., Sacks-Davis, R., van Santen, D. K., Smit, C., Martinello, M., Stoove, M., Berenguer, J., Wittkop, L., Klein, M. B., Rauch, A., Salmon, D., Lacombe, K., Stewart, A., Schinkel, J., Doyle, J. S., Hellard, M., van der Valk, M., & Matthews, G. V. (2023). Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study. https://doi.org/10.48350/180676

Chicago

Isfordink, Cas J, Anders Boyd, Rachel Sacks-Davis, Daniela K van Santen, Colette Smit, Marianne Martinello, Mark Stoove, et al. 2023. “Reasons for Not Commencing Direct-Acting Antiviral Treatment despite Unrestricted Access for Individuals with HIV and Hepatitis C Virus: A Multinational, Prospective Cohort Study,” January. doi:10.48350/180676.